



Alex A. Adjei, MD;PhD, FACP, FASCO

Professor of Oncology
Professor of Pharmacology
Director, Early Cancer Therapeutics
Director, Global Oncology
Mayo Clinic, Rochester, MN, USA

Alex A. Adjei is a Consultant in Oncology, Professor of Oncology and Professor of Pharmacology at Mayo Clinic. He is Director of Early Cancer Therapeutics, and Principal Investigator (PI) of the Mayo Clinic Phase I UM1 and Phase II supplement grants from the National Cancer Institute (US). He is also co-Leader of the Developmental Therapeutics Program and leader of the Lung Cancer Program at Mayo Cancer Center. Dr. Adjei has served on the ASCO Task Force on Translational Research; multiple National Institutes of Health study sections, including the CTSA study section (chair, 2007-2011); the Clinical Oncology study section (member, 2008-2012) and Subcommittee A reviewing cancer centers (member, 2013-2017); and the AACR Annual Meeting Committee (co-Chair, 2005, 2007, and 2012). He has been involved in crucial phase I studies of topotecan, irinotecan, temsirolimus, gemcitabine, pemetrexed, gefitinib and bortezomib. As the PI on over 70 phase I trials, he has also performed important studies of sorafenib, antisense oligonucleotides, PI3-kinase inhibitors, and MEK inhibitors. He continues in his national and international senior leadership role in lung cancer as co-Chair of the NCI Thoracic Malignancies Steering Committee, and co-Chair of NCI Clinical Trials Advisory Committee Small Cell Lung Cancer working group (2019). He has served as a member of the board of directors of the International Association for the Study of Lung Cancer (IASLC) and he is Editor-in-Chief of the *Journal of Thoracic Oncology*.

Dr Adjei's research is focused on experimental therapeutics and clinical drug development.

He has a passion for mentorship and has mentored over 50 junior colleagues both nationally and internationally to become future leaders in clinical and translational research. He received the first American Society of Clinical Oncology Drug Development Research Professorship 2012-2017, in recognition of his mentorship and his work in cancer drug development. He has authored 270 publications dealing primarily with preclinical pharmacology and phase I trials as well as novel therapies for lung cancer.